
SPTX Stock Forecast & Price Target
SPTX Analyst Ratings
Bulls say
Seaport Therapeutics is a strong potential investment due to its innovative and promising products in the neuropsychiatric disorder market, including GlyphAllo, Glyph2BLSD, and GlyphAgo. The company's focus on bypassing first-pass metabolism and reducing side effects makes their drugs stand out in the crowded prescription market. With a successful Phase 1 trial and a favorable outlook, Seaport has potential for growth and acquisition, solidifying its position as a leader in the treatment of depression, anxiety, and other neuropsychiatric disorders.
Bears say
Seaport Therapeutics is facing potential challenges in the rapidly advancing clinical programs for its two most mature clinical-stage assets, which may lead to delayed key catalysts expected in the next several quarters. Additionally, the company's planned Phase 2b trials for its pipeline products are not expected to yield results until 2028, causing potential concerns for investors. The company also faces competition from other companies developing innovative treatments in the neuropsychiatry space.
This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SPTX Analyst Forecast & Price Prediction
Start investing in SPTX
Order type
Buy in
Order amount
Est. shares
0 shares